CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety and best dose of CC-486 (an oral form of azacitidine)
when given together with nivolumab in treating patients with Hodgkin lymphoma that does not
respond (refractory) to PD1-based immunotherapy or has come back (relapsed). CC-486 is in a
class of medications called demethylation agents. It works by helping the bone marrow to
produce normal blood cells and by killing abnormal cells. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving CC-486 in combination
with nivolumab may render nivolumab more effective.